HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., May 25, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM;…
Strong anti-tumor activity shown in a platinum-resistant ovarian cancer population, with a confirmed ORR of 50.0% and mPFS of 7.4…
Preliminary signs of antitumor activity noted in 36% of patients, with two partial responses (PR) and seven patients with prolonged…
- SL-172154 demonstrated favorable safety and tolerability profile across doses, with maximal CD47 and CD40 target engagement and CD40-dependent pharmacodynamic…
Media ReleaseCOPENHAGEN, Denmark; May 25, 2023 Oral presentations will highlight epcoritamab-bysp in combination with rituximab-lenalidomide (R2) in high-risk follicular lymphomaPoster…
- Nirogacestat Treatment Demonstrated Rapid, Sustained and Consistent Reductions in Pain Compared to Placebo Using Multiple Assessment Tools - -…
71% objective response rate, with 59% of patients achieving a very good partial response or better at the recommended 200…
NEW YORK, May 25, 2023 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a…
Treatment with BDC-1001 at the recommended Phase 2 dose (RP2D) resulted in 29% objective response rate in evaluable patients with…
ASCO abstract highlights 50% partial response and 100% disease control rates in evaluable desmoid tumor patients treated with AL102 1.2…